Alcoholic Hepatitis Clinical Trial
— SFAHOfficial title:
Effect of Saturated Fat (Desi Ghee) on Gut-Liver Axis in Alcoholic Hepatitis
Verified date | February 2022 |
Source | Institute of Liver and Biliary Sciences, India |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The pathogenesis of the alcoholic liver disease (ALD) is a complex interplay of various etiopathological factors other than direct alcohol toxicity. These factors include inflammation & oxidative stress, dysbiosis, intestinal hyperpermeability, and endotoxemia. Dietary fats not only improve nutritional status in ALD but specific properties of saturated fats (SF) have the potential to favourably modulate these causative factors. This project has two parts, in the animal study 10 groups of murine model of alcoholic hepatitis (AH) would be given SF in the form of Desi Ghee and in the human study patients with AH would be randomized into two groups, one with SF ( Desi Ghee) and the other with usual unsaturated fat (cooking oil). In all effect of SF on gut microbiota, hepatic steatosis, TLR-4 expression, serum adiponectin, endotoxin levels, intestinal tight junction proteins and inflammatory markers in murine models of AH, along with hepatic morbidity & lipid profile, in patients with ALD would be studied.
Status | Completed |
Enrollment | 60 |
Est. completion date | January 31, 2022 |
Est. primary completion date | January 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: All patients with Severe Alcoholic Hepatitis - Aged between 18-60 years - Having Maddrey Score of >32 - Last Intake of alcohol from 1 day to 60days - Patients who agree for complete alcohol abstinence from the day of enrollment Exclusion Criteria: Patients with- - Maddrey Score of <32 and >100 - Comorbidities- Diabetes, Hypertension, Coronary Artery Disease, Chronic Kidney Disease, Hypothyroid - Continuing Alcohol intake- Non-compliant patients - Constipation - On Laxatives until 1 month prior to study - On probiotics until 1 month prior to study |
Country | Name | City | State |
---|---|---|---|
India | Institute of Liver and Biliary Sciences | New Delhi | Delhi |
Lead Sponsor | Collaborator |
---|---|
Institute of Liver and Biliary Sciences, India |
India,
Chen P, Torralba M, Tan J, Embree M, Zengler K, Stärkel P, van Pijkeren JP, DePew J, Loomba R, Ho SB, Bajaj JS, Mutlu EA, Keshavarzian A, Tsukamoto H, Nelson KE, Fouts DE, Schnabl B. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. Gastroenterology. 2015 Jan;148(1):203-214.e16. doi: 10.1053/j.gastro.2014.09.014. Epub 2014 Sep 16. — View Citation
Edenberg HJ. The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants. Alcohol Res Health. 2007;30(1):5-13. Review. — View Citation
Hritz I, Mandrekar P, Velayudham A, Catalano D, Dolganiuc A, Kodys K, Kurt-Jones E, Szabo G. The critical role of toll-like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88. Hepatology. 2008 Oct;48(4):1224-31. doi: 10.1002/hep.22470. — View Citation
Keshavarzian A, Farhadi A, Forsyth CB, Rangan J, Jakate S, Shaikh M, Banan A, Fields JZ. Evidence that chronic alcohol exposure promotes intestinal oxidative stress, intestinal hyperpermeability and endotoxemia prior to development of alcoholic steatohepatitis in rats. J Hepatol. 2009 Mar;50(3):538-47. doi: 10.1016/j.jhep.2008.10.028. Epub 2008 Dec 29. — View Citation
Kirpich IA, Feng W, Wang Y, Liu Y, Barker DF, Barve SS, McClain CJ. The type of dietary fat modulates intestinal tight junction integrity, gut permeability, and hepatic toll-like receptor expression in a mouse model of alcoholic liver disease. Alcohol Clin Exp Res. 2012 May;36(5):835-46. doi: 10.1111/j.1530-0277.2011.01673.x. Epub 2011 Dec 7. — View Citation
Kirpich IA, Petrosino J, Ajami N, Feng W, Wang Y, Liu Y, Beier JI, Barve SS, Yin X, Wei X, Zhang X, McClain CJ. Saturated and Unsaturated Dietary Fats Differentially Modulate Ethanol-Induced Changes in Gut Microbiome and Metabolome in a Mouse Model of Alcoholic Liver Disease. Am J Pathol. 2016 Apr;186(4):765-76. doi: 10.1016/j.ajpath.2015.11.017. — View Citation
Kirpich IA, Solovieva NV, Leikhter SN, Shidakova NA, Lebedeva OV, Sidorov PI, Bazhukova TA, Soloviev AG, Barve SS, McClain CJ, Cave M. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol. 2008 Dec;42(8):675-82. doi: 10.1016/j.alcohol.2008.08.006. — View Citation
Mutlu E, Keshavarzian A, Engen P, Forsyth CB, Sikaroodi M, Gillevet P. Intestinal dysbiosis: a possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats. Alcohol Clin Exp Res. 2009 Oct;33(10):1836-46. doi: 10.1111/j.1530-0277.2009.01022.x. Epub 2009 Jul 23. — View Citation
Nanji AA, Jokelainen K, Tipoe GL, Rahemtulla A, Dannenberg AJ. Dietary saturated fatty acids reverse inflammatory and fibrotic changes in rat liver despite continued ethanol administration. J Pharmacol Exp Ther. 2001 Nov;299(2):638-44. — View Citation
Su GL, Rahemtulla A, Thomas P, Klein RD, Wang SC, Nanji AA. CD14 and lipopolysaccharide binding protein expression in a rat model of alcoholic liver disease. Am J Pathol. 1998 Mar;152(3):841-9. — View Citation
Zhong W, Li Q, Xie G, Sun X, Tan X, Sun X, Jia W, Zhou Z. Dietary fat sources differentially modulate intestinal barrier and hepatic inflammation in alcohol-induced liver injury in rats. Am J Physiol Gastrointest Liver Physiol. 2013 Dec;305(12):G919-32. doi: 10.1152/ajpgi.00226.2013. Epub 2013 Oct 10. — View Citation
* Note: There are 11 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | To study the serum pro- inflammatory marker, TNF-alpha in patients with severe alcoholic hepatitis | The collected blood sample would be assessed for TNF- alpha levels by using Quantikine ELISA kit | 2 months | |
Other | To study the serum pro- inflammatory marker, IL-6 in patients with severe alcoholic hepatitis | The collected blood sample would be assessed for IL-6 levels by using Quantikine ELISA kit | 2 months | |
Other | To study the serum pro- inflammatory marker, NF-kB in patients with severe alcoholic hepatitis | The collected blood sample would be assessed for NF-kB levels by using Quantikine ELISA kit | 2 months | |
Other | To study the serum anti- inflammatory marker,adiponectin in patients with severe alcoholic hepatitis | The collected blood sample would be assessed for adiponectin levels by using Quantikine ELISA kit | 2 months | |
Other | To study the serum anti- inflammatory marker, IL-10 in patients with severe alcoholic hepatitis | The collected blood sample would be assessed for IL-10 levels by using Quantikine ELISA kit | 2 months | |
Other | To observe the expression of gut microbiome specific genes in patients with severe alcoholic hepatitis | The stool sample collected would be assessed for Fab genes (G and F) expression using 16s ribosomal gene sequencing. | 2 months | |
Other | To observe Clinical benefit in patients of severe alcoholic hepatitis | Clinical benefit in terms of resolution of signs & symptoms to be observed. | 2 months | |
Other | To observe Clinical benefit in patients of severe alcoholic hepatitis | Clinical benefit in terms of improvement in Bilirubin levels to be observed | 2 months | |
Other | To observe Clinical benefit in patients of severe alcoholic hepatitis | Clinical benefit in terms of reduction of AST & ALT levels to be observed | 2 months | |
Other | To observe Clinical benefit in patients of severe alcoholic hepatitis | Clinical benefit in terms of reduction Maddrey Score to be observed | 2 months | |
Other | To observe the Nutritional status in patients with Severe Alcoholic hepatitis | Body composition analysis by BIA (Bioelectrical impedance analysis) for nutritional screening of the patients | 2 months | |
Primary | To determine the improvement in cirrhosis dysbiosis ratio (CDR) associated with saturated fat in patients with severe alcoholic hepatitis. | The stool sample of the patients would be processed by 16s ribosomal RNA Gene sequencing to observe the diversity, abundance an evenness of the microbial community and thereafter Cirrhosis dysbiosis ratio (CDR) would be calculated at the starting and the end of the study i.e at baseline and at the end of two months. | 2 months | |
Secondary | To study the serum endotoxin (lipoploysacchride) levels in patients with severe alcoholic hepatitis | The collected blood sample would be assessed for endotoxin levels by using Toxin Sensor TM Chromogenic LAL Endotoxin Assay Kit | 2 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04066179 -
Efficacy of Monotherapy vs Combination Therapy of Corticosteroids With GCSF in Severe Alcoholic Hepatitis Patients.
|
N/A | |
Completed |
NCT03732586 -
Effect of Omega 5 Fatty Acid as an Adyuvant Treatment to Prednisone in Patients With Severe Alcoholic Hepatitis
|
N/A | |
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Completed |
NCT00962442 -
N-Acetylcysteine in Severe Acute Alcoholic Hepatitis
|
Phase 3 | |
Not yet recruiting |
NCT06307522 -
MRG-001 in Patients With Alcoholic Hepatitis
|
Phase 2 | |
Recruiting |
NCT05018481 -
HA35 Moderate Alcoholic Hepatitis (AH) Study
|
Early Phase 1 | |
Completed |
NCT04544020 -
Changes in gUt micRobiota After Enteral Feeding (in Alcoholic Hepatitis)
|
||
Recruiting |
NCT04088370 -
Peripheral Blood Mononuclear Cells Response In Healthy Controls, Heavy Drinkers, and Patients With Alcoholic Hepatitis
|
||
Completed |
NCT04235855 -
EUS Guided Liver Biopsy - Will it Give Better Yield, More Tissue With Less Complication?
|
N/A | |
Active, not recruiting |
NCT02344680 -
Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
|
||
Completed |
NCT00851981 -
Randomized, Controlled Trial of S-adenosylmethionine in Alcoholic Liver Disease
|
Phase 2 | |
Completed |
NCT05840640 -
Granulocyte Colony Stimulating Factor Four Week Plus N-Acetyl Cysteine in Severe Alcoholic Hepatitis
|
Phase 4 | |
Recruiting |
NCT03069300 -
N-ACetylcysteine to Reduce Infection and Mortality for Alcoholic Hepatitis
|
Phase 3 | |
Terminated |
NCT02039219 -
Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH)
|
Phase 2 | |
Completed |
NCT01245257 -
Effects of Prednisolone and Pentoxifylline on the Regulation of Urea Synthesis in Alcoholic Hepatitis
|
N/A | |
Completed |
NCT02019056 -
Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis
|
Phase 2 | |
Completed |
NCT00388323 -
Adipose Tissue Involvement in Alcohol-induced Liver Inflammation in Human
|
N/A | |
Recruiting |
NCT03845205 -
Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH
|
N/A | |
Recruiting |
NCT03703674 -
GCSF in Alcoholic Hepatitis
|
Phase 4 | |
Active, not recruiting |
NCT02473341 -
Comparison of Bovine Colostrum Versus Placebo in Treatment of Severe Alcoholic Hepatitis: A Randomized Double Blind Controlled Trial
|
Phase 3 |